Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 652 of 5804
-
Triple threat: could adding radiation to immunotherapy and chemotherapy help fight advanced lung cancer?
Disease control Recruiting nowThis this study is for individuals who have treatment-naïve extensive-stage small cell lung cancer (small cell lung cancer that wont respond to treatment). Doctors leading this study hope to learn if combining durvalumab, carboplatin and etoposide with hyofractionated ablative ra…
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug shows promise for stiff heart condition in japanese patients
Disease control CompletedThe purpose of this study is to evaluate the effectiveness, safety, and tolerability of a 30-week course of mavacamten and the long-term effects of mavacamten in Japanese participants with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for kids with rare cancers: brigatinib trial opens
Disease control Recruiting nowThis is an open-label, phase I-II dose-escalation and expansion study designed to define the recommended dose of brigatinib as monotherapy in pediatric and young adult patients with ALK+ ALCL, IMT or other solid tumors and to evaluate the pharmacokinetics (PK), (long-term) safety…
Phase: PHASE1, PHASE2 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New drug combo shows promise for untreatable liver tumors
Disease control OngoingTo evaluate the efficacy and safety of Donafenib plus Sintilimab in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma(HCC).
Phase: PHASE2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to tackle tough cancers
Disease control Recruiting nowBackground: Aldesleukin is used to treat metastatic or advanced melanoma and renal cell carcinoma. Pembrolizumab is used to treat many cancers including melanoma. Researchers want to see if these drugs can be used together to produce better results in people with these types of …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Experimental combo therapy aims to outsmart leukemia without dangerous side effects
Disease control OngoingTo assess the safety of administering allogenic, donor-derived CD19/CD22-CAR T cells that meet established release specifications in adults with B-cell ALL following a myeloablative conditioning regimen and Orca-T to determine if this will augment graft versus leukemia without in…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat brain cancer
Disease control OngoingRelapsed or refractory primary DLBCL of the CNS
Phase: PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to keep bladder cancer at bay after chemo
Disease control OngoingThe purpose of this study is to assess the safety and efficacy of avelumab in combination with other anti-tumor agents as a maintenance treatment in participants with bladder cancer.
Phase: PHASE2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill shows promise in controlling blood sugar for type 2 diabetes
Disease control CompletedA Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMF-219, an Oral Covalent Menin Inhibitor, in Healthy Adult Subjects and in Adult Subjects with Type 2…
Phase: PHASE1, PHASE2 • Sponsor: Biomea Fusion Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New combo therapy aims to tackle Tough-to-Treat myeloma
Disease control Recruiting nowThis study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with mult…
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug combo shows promise for Tough-to-Treat breast cancer
Disease control OngoingThe purpose of this study is to assess the safety and tolerability and preliminary antitumor activity of SKB264 with/without KL-A167 in patients with unresectable locally advanced, recurrent or metastatic TNBC and HR+/HER2- BC .The study is divided into three parts.Part 1(TNBC): …
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Brain cancer boost: radioactive tile added to standard therapy in new trial
Disease control OngoingIn summary, standard of care postoperative chemoradiation for patients with newly diagnosed GBM does not routinely provide durable local control or prolonged overall survival. As discussed above it seems unlikely that patient outcomes will be significantly improved with radiation…
Phase: PHASE4 • Sponsor: GT Medical Technologies, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:19 UTC
-
New engineered graft aims to improve stem cell transplants for kids with leukemia
Disease control TerminatedThis is a first in children prospective study of allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q). The study will assess safety and efficacy of Orca-Q in pediatric patients with hematologic malignancies.
Phase: PHASE1, PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug ABBV-916 aims to slow Alzheimer's in early stages
Disease control CompletedAlzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or …
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Weekly shot helps asians with obesity shed pounds in major trial
Disease control CompletedThis study looks at how well semaglutide helps people lose weight. This study will look at the change in the participants' body weight from the start to the end of the study. The study compares the weight loss in people who get semaglutide to the weight loss in people who get pla…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Immune cell therapy shows promise for tough leukemia cases
Disease control TerminatedThis is an open-label, phase II study designed to evaluate the efficacy and effectiveness of TCB008 in patients with Acute Myeloid Leukemia (AML), or Myelodysplastic Syndromes (MDS)/AML, with either refractory or relapsed disease. Five patients will be recruited for an initial s…
Phase: PHASE2 • Sponsor: TC Biopharm • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New pill could tame blistering skin disease without high steroid doses
Disease control OngoingONO-4059-10:Multicenter, placebo-controlled, randomized, double-blind, Phase 3 study in patients with steroid-resistant pemphigus
Phase: PHASE3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New MRI method could revolutionize prostate cancer screening for High-Risk men
Diagnosis Recruiting nowTo determine whether using bpMRI in subjects who are at high risk of developing prostate cancer in conjunction with PSA will improve prostate cancer screening protocols.
Phase: NA • Sponsor: Northwell Health • Aim: Diagnosis
Last updated Jun 27, 2026 07:59 UTC
-
New antibody-chemo combo shows promise for mesothelioma
Disease control CompletedPM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with pemetrexed and platinum as first line treatment for MPM.
Phase: PHASE2 • Sponsor: Biotheus Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Sound waves may help cancer drugs reach the brain
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved, on-label systemic therapy utilizing immu…
Phase: PHASE3 • Sponsor: InSightec • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC